There is no definitive test for dsDNA; however, the anti-dsDNA Elisa is a highly specific blood test used to identify rheumatic diseases. Anti-DSDNA Elisa results can be used to confirm or rule out SLE, a disease that has increased frequency and severity in recent years. In addition to detecting DSDNA, Elisa results can also be useful in identifying other rheumatic diseases, such as sarcoidosis, multiple sclerosis, and lupus erythematosus.
The Anti-dsDNA-NcX ELISA is free of the proteins Scl-70 and histone H1. It was compared to a Farr assay and serum samples from 964 people. ROC curve analysis was used to compare the two tests. In general, Anti-dsDNA-NcX ELISA is superior to anti-dsDNA-NcX.
The FEIA dsDNA immunoassay is an excellent diagnostic test for SLE. It has a high specificity of 90 percent, which is required by the revised EULAR/ACR criteria for diagnosis of SLE. It also provides fast and accurate results. The anti-dsDNA-NcX ELISA demonstrates superior performance compared to the immunofluorescent test, but is not as accurate as the Farr assay.
The ANA test is preferable for investigational purposes. When a patient is suspected of having a systemic autoimmune disease, the ANA test is usually preferable. The Anti-dsDNA ELISA is also useful in detecting patterns in healthy individuals. In the case of a positive ANA test, the patient's immune system should be tested to confirm the diagnosis.
An anti-dsDNA blood test is a valuable tool for confirming the diagnosis of lupus. Patients with lupus will have a higher level of anti-dsDNA during flare-ups. It is also useful for monitoring lupus nephritis, as the disease can affect the kidneys. As a result, protein can accumulate in the urine, leading to high blood pressure.
Although anti-dsDNA is the most reliable diagnostic tool for detecting SLE, it has some limitations. Many of the patients studied were referred to this laboratory through primary care or secondary care. In such cases, the results may be misleading. A diagnosis of SLE may be impossible without an accurate blood test, but a DSDNA anti-dsDNA antigen test will be helpful to differentiate the disease. There maybe some residual substances on the ELISA plate after detetion. In order to reduce the errors caused by the residues, a plate washer is needed, which is a medical device specially designed to clean the microplate and generally used in conjunction with the microplate reader.
In this systematic review, we identified 30 citations. Six studies reported dsDNA data, and six were eligible for inclusion in a quantitative meta-analysis. These six studies included a total of 1977 patients. A significant proportion of patients with SLE had their diagnosis confirmed using the reference standard. Despite the high number of patients, all studies were based in Europe. The PRISMA diagram shows the flow of citations.
The rate at which anti-dsDNA antibody levels increased in PLN was also analyzed. In this study, the rate at which these antibodies increased was 70 percent versus zero. In addition, patients with elevated levels of C-reactive protein showed an increased level before the anti-dsDNA antibody levels. Most of these patients had an elevated anti-dsDNA level antecedent to a PLN diagnosis.
The percentage of patients with PLN with elevated anti-dsDNA antibodies prior to diagnosis was higher than that of those with SLE without LN. Additionally, in the present study, anti-dsDNA antibody levels were elevated ten to fifteen months before a PLN flare. One control with SLE without LN was also positive for anti-dsDNA antibodies less than a year before diagnosis, and thus, could develop PLN at a later date.